Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation

The application of mesenchymal stromal cell (MSC)-based therapy during ex vivo lung perfusion (EVLP) could repair injured donor lungs prior to transplantation. The aim of this study was to determine the efficacy of MSC therapy performed during EVLP on ischemia-reperfusion injury using a pig lung transplant model.

Source: The Journal of Heart and Lung Transplantation - July 25, 2019 Category: Transplant Surgery Authors: Daisuke Nakajima, Yui Watanabe, Akihiro Ohsumi, Mauricio Pipkin, Manyin Chen, Pierre Mordant, Takashi Kanou, Tomohito Saito, Ryan Lam, Rafael Coutinho, Lindsay Caldarone, Stephen Juvet, Tereza Martinu, Rohin K. Iyer, John E. Davies, David M. Hwang, Thomas Tags: Original Pre-Clinical Science Source Type: research